Even without input from the Oncology Care Model, community practices can measure performance data through a robust electronic medical record like Flatiron, said Erich Mounce, chief operating officer, OneOncology.
Even without input from the OCM, community practices can measure performance data through a robust electronic medical record like Flatiron, said Erich Mounce, chief operating officer, OneOncology.
Transcript
For community practices not involved in models like the OCM [Oncology Care Model], is it difficult to measure practice performance? What are the best ways to do this?
I don’t know if it’s difficult, I think they can do it. From my perspective they need to invest in a really robust electronic medical record, Flatiron would be a perfect example of that, and make sure they’re getting data from all of their clinical measurements, as well as, the revenue cycle measurements—I think those are really important pieces. Whether you’re an OCM or not, you can still measure your staging data, you can still measure your MIPs [merit-based incentive payment system] data, you can still measure your patient satisfaction data. I think that you should measure how you’re adhering to your own care pathways or your own regimens. Those are all things that allow you to measure your performance on a clinical basis, but also from a financial performance basis. So, absolutely you can do it. The real issue is, are you able to have enough data to really cycle through a process that is statistically relevant, number 1, and 2 is investing to get that data sometimes is really expensive. So, for group practices, they don’t want to become IT companies or data companies—I really think they need to come back full circle to your first question [of] what do I get out of a partnership, how do I survive—and that partnership I think is really important to get those kinds of things.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More